Table 5.
Summary of evidence-based cancer therapy by MSC as deduced by the meta-analysis of peer-reviewed experimental/ preclinical research studies
| MSC | MSC GM status # | Tumor target | Effect on tumor target | Evidence in support |
|---|---|---|---|---|
| AT | Modified (or naïve) | Neural | Suppression | ** |
| UC | Naïve (or modified) | Breast | Suppression | *** |
| UC | Modified (or naïve) | Lung | Suppression | ** |
| BM | Modified | Neural | Suppression | ** |
| BM | Modified | Lung | Suppression | ** |
| BM | Modified (or naïve) | Pancreas | Suppression | * |
| BM | Naïve | Breast | Promotion | *** |
| BM | Naïve | Osteosarcoma | Promotion | * |
# Primary or secondary/minor (in brackets) contribution of the genetic modification status of the MSC to the overall observed effect on tumor target
No. of studies *≥ 3, **≥ 6, ***≥ 10